[To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver].

Abstract

OBJECTIVE:

To explore relations between the opportunities and effects of internal general treatment added Entecavir on acute-on-chronic liver failure (ACLF) of HBeAg-negative chronic hepatitis B in different score ranges of acute-on-chronic liver failure severity.

METHODS:

A total of 108 ACLF of HBeAg-negative chronic hepatitis B patients with different ACLF severity score were treated with internal general treatment added Entecavir. The liver failure severity scores, HBV-DNA loads during the initiation of therapy, recovery phase and in deathbed phase, courses of Entecavir administration and mortalities were studied.

RESULTS:

For 19 patients with high ACLF score (> or = 12), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was not significant and the mortality was 18/19. For 30 patients with higher intermediate ACLF score (8-11), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 66.67% (20/30). For 36 patients with lower intermediate ACLF score (5-7), the difference in ACLF score between pre and posttreatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 30.56% (11/36). For 23 patients with low ACLF score (< or = 4), the difference in ACLF score between pre and post-treatment was significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 8.70% (2/23).

CONCLUSIONS:

A novel acute-on-chronic liver failure scoring system can syllabify differentiate the relations between the opportunities and efficacies on the Entecavir treatment for HBeAg-negative ACLF.

• Authors: Li Mai, Ying Yan, Shao-Quan Zhang, Wei-Min Ke, Hong Cao
• Journal: Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology (Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi) Vol. 27 Issue 4 Pg. 286-8 (Aug 2013) ISSN: 1003-9279 [Print] China
• PMID: 24579477 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Hepatitis B e Antigens
• entecavir
• Guanine

Topics

• Adult
• Aged
• Antiviral Agents (therapeutic use)
• Female
• Guanine (analogs & derivatives, therapeutic use)
• Hepatitis B e Antigens (blood)
• Hepatitis B virus (genetics, isolation & purification, metabolism)
• Hepatitis B, Chronic (blood, drug therapy, virology)
• Humans
• Liver Failure (blood, drug therapy, virology)
• Male
• Middle Aged